The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...
CSL Limited trades at a decade-low P/E, despite ongoing revenue and profit growth, presenting significant upside potential. Learn more about CMXHF stock here.
CSL says plasma donors can earn up to $100 per donation and as much as $750 per month. Here’s how it works and what to watch ...
94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal ...
HEMGENIX ® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained efficacy and safety at three years ...
MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global ...
HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus ...
- 4- and 5-gram ZEMAIRA® vials may reduce the number of vials necessary for reconstitution, thereby providing convenience and lowering package waste KING OF PRUSSIA, Pa., Jan. 2, 2024 /PRNewswire/ -- ...
In recognition of Rare Disease Day and as part of its ongoing commitment to the global bleeding disorders community, CSL Behring announced today that it is donating 2 million international units (IUs) ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Hemgenix will have a list price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results